All In Biotech

Drug Trial Radar · NCT02782104

A Long-term Safety Study of Esketamine Nasal Spray in Treatment-resistant Depression

An Open-label Long-term Extension Safety Study of Esketamine Nasal Spray in Treatment-resistant Depression

Last checked: Nov 20, 2026Latest source record: Apr 29, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,148

Actual

Start

Jun 9, 2016

Primary completion

Dec 30, 2022

Study completion Dec 30, 2022

Sponsor

Lead sponsor
Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
Sponsor type
Industry
First posted
May 25, 2016

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to assess the safety and tolerability of esketamine nasal spray in participants with treatment-resistant depression (TRD).

Conditions

  • Depressive Disorder, Treatment-Resistant

Interventions

  • Esketamine Nasal SprayDrug

    Open-Label Induction Phase: Participants will self-administer with esketamine nasal spray twice per week for 4 weeks as a flexible dose regimen (56 milligram \[mg\] or 84 mg for those \< 65 years; 28 mg, 56 mg or 84 mg for those \>= 65 years). Participants \>= 65 years old will start at a dose of 28 mg on Day 1. Optimization/Maintenance Phase: Participants entering from studies ESKETINTRD3001 (NCT02417064), ESKETINTRD3002 (NCT02418585) or ESKETINTRD3006 (US sites only) will self-administer esketamine nasal spray (same dose) once weekly. Participants entering from study ESKETINTRD3005 (NCT02422186) will self-administer esketamine nasal spray (28 mg in week 1; 28 or 56 mg in week 2; and 28, 56 or 84 mg in week 3 and 4) once weekly. After Week 4 (starting at Week 5), based on the Investigator's clinical judgment, the dose of esketamine for all participants can be adjusted based upon efficacy and tolerability.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change From Study Baseline in Computerized Cognitive Battery Domain Score: Detection Test (DET) ScoreTime frame: IND Phase: Baseline up to 4 weeks; OP/MA Phase: Baseline up to 78 months
  2. Change From Study Baseline in Computerized Cognitive Battery Domain Score: Identification Test (IDN) ScoreTime frame: IND Phase: Baseline up to 4 weeks; OP/MA Phase: Baseline up to 78 months
  3. Change From Study Baseline in Computerized Cognitive Battery Domain Score: One Card Learning Test (OCL) ScoreTime frame: IND Phase: Baseline up to 4 weeks; OP/MA Phase: Baseline up to 78 months
  4. Change From Study Baseline in Computerized Cognitive Battery Domain Score: One Back Test (ONB) ScoreTime frame: IND Phase: Baseline up to 4 weeks; OP/MA Phase: Baseline up to 78 months
  5. Change From Study Baseline in Computerized Cognitive Battery Domain Score: Groton Maze Learning Test (GMLT) ScoreTime frame: IND Phase: Baseline up to 4 weeks; OP/MA Phase: Baseline up to 78 months
  6. Change From Study Baseline in Hopkins Verbal Learning Test-Revised (HVLT-R) ScoreTime frame: IND Phase: Baseline up to 4 weeks; OP/MA Phase: Baseline up to 78 months
  7. Percentage of Participants Based on Columbia-Suicide Severity Rating Scale (C-SSRS) ScoreTime frame: IND Phase: Baseline up to 4 weeks; OP/MA Phase: Baseline up to 78 months
  8. Number of Participants With Treatment-emergent Adverse Events (TEAEs)Time frame: IND Phase: up to 4 weeks; OP/MA Phase: up to 78 months
  9. Change From Baseline in Heart RateTime frame: IND Phase: Baseline up to 4 weeks; OP/MA Phase: Baseline up to 78 months
  10. Change From Baseline in Systolic and Diastolic Blood PressureTime frame: IND Phase: Baseline up to 4 weeks; OP/MA Phase: Baseline up to 78 months
  11. Change From Baseline in Respiratory RateTime frame: IND Phase: Baseline up to 4 weeks; OP/MA Phase: Baseline up to 78 months
  12. Change From Baseline in Blood Oxygen SaturationTime frame: IND Phase: Baseline up to 4 weeks; OP/MA Phase: Baseline up to 78 months

Locations

173 sites in 26 countries. Site status is shown where the registry gives one.

  • Site not named

    Birmingham, Alabama

  • Site not named

    Little Rock, Arkansas

  • Site not named

    Garden Grove, California

  • Site not named

    Glendale, California

  • Site not named

    Oakland, California

  • Site not named

    Orange, California

  • Site not named

    San Diego, California

  • Site not named

    San Rafael, California

  • Site not named

    Hartford, Connecticut

  • Site not named

    New Haven, Connecticut

  • Site not named

    Gainesville, Florida

  • Site not named

    Miami, Florida

  • Site not named

    Orlando, Florida

  • Site not named

    Atlanta, Georgia

  • Site not named

    Chicago, Illinois

  • Site not named

    Hoffman Estates, Illinois

  • Site not named

    Joliet, Illinois

  • Site not named

    Maywood, Illinois

  • Site not named

    Skokie, Illinois

  • Site not named

    Iowa City, Iowa

  • Site not named

    Wichita, Kansas

  • Site not named

    Lake Charles, Louisiana

  • Site not named

    Shreveport, Louisiana

  • Site not named

    Baltimore, Maryland

  • Site not named

    Gaithersburg, Maryland

  • Site not named

    Boston, Massachusetts

  • Site not named

    New Bedford, Massachusetts

  • Site not named

    Watertown, Massachusetts

  • Site not named

    Worcester, Massachusetts

  • Site not named

    Rochester Hills, Michigan

  • Site not named

    O'Fallon, Missouri

  • Site not named

    Saint Charles, Missouri

  • Site not named

    Omaha, Nebraska

  • Site not named

    Cedarhurst, New York

  • Site not named

    New York, New York

  • Site not named

    Staten Island, New York

  • Site not named

    Hickory, North Carolina

  • Site not named

    Cincinnati, Ohio

  • Site not named

    Oklahoma City, Oklahoma

  • Site not named

    Allentown, Pennsylvania

Showing 40 of 173 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.